Salpingectomy and the Risk of Ovarian Cancer in Ontario
- PMID: 37566421
- PMCID: PMC10422181
- DOI: 10.1001/jamanetworkopen.2023.27198
Salpingectomy and the Risk of Ovarian Cancer in Ontario
Abstract
Importance: A body of pathological and clinical evidence supports the position that the fallopian tube is the site of origin for a large proportion of high-grade serous ovarian cancers. Consequently, salpingectomy is now considered for permanent contraception (in lieu of tubal ligation) or ovarian cancer prevention (performed opportunistically at the time of surgical procedures for benign gynecologic conditions).
Objective: To evaluate the association between salpingectomy and the risk of invasive epithelial ovarian, fallopian tube, and peritoneal cancer.
Design, setting, and participants: This population-based retrospective cohort study included all women aged 18 to 80 years who were eligible for health care services in Ontario, Canada. Participants were identified using administrative health databases from Ontario between January 1, 1992, and December 31, 2019. A total of 131 516 women were included in the primary (matched) analysis. Women were followed up until December 31, 2021.
Exposures: Salpingectomy (with and without hysterectomy) vs no pelvic procedure (control condition) among women in the general population.
Main outcomes and measures: Women with a unilateral or bilateral salpingectomy in Ontario between April 1, 1992, and December 31, 2019, were matched 1:3 to women with no pelvic procedure from the general population. Cox proportional hazards regression models were used to estimate the hazard ratios (HRs) and 95% CIs for ovarian, fallopian tube, and peritoneal cancer combined.
Results: Among 131 516 women (mean [SD] age, 42.2 [7.6] years), 32 879 underwent a unilateral or bilateral salpingectomy, and 98 637 did not undergo a pelvic procedure. After a mean (range) follow-up of 7.4 (0-29.2) years in the salpingectomy group and 7.5 (0-29.2) years in the nonsurgical control group, there were 31 incident cancers (0.09%) and 117 incident cancers (0.12%), respectively (HR, 0.82; 95% CI, 0.55-1.21). The HR for cancer incidence was 0.87 (95% CI, 0.53-1.44) when comparing those with salpingectomy vs those with hysterectomy alone.
Conclusions and relevance: In this cohort study, no association was found between salpingectomy and the risk of ovarian cancer; however, this observation was based on few incident cases and a relatively short follow-up time. Studies with additional years of follow-up are necessary to define the true level of potential risk reduction with salpingectomy, although longer follow-up will also be a challenge unless collaborative efforts that pool data are undertaken.
Conflict of interest statement
Figures


Similar articles
-
No. 344-Opportunistic Salpingectomy and Other Methods of Risk Reduction for Ovarian/Fallopian Tube/Peritoneal Cancer in the General Population.J Obstet Gynaecol Can. 2017 Jun;39(6):480-493. doi: 10.1016/j.jogc.2016.12.005. J Obstet Gynaecol Can. 2017. PMID: 28527613
-
Examining indicators of early menopause following opportunistic salpingectomy: a cohort study from British Columbia, Canada.Am J Obstet Gynecol. 2020 Aug;223(2):221.e1-221.e11. doi: 10.1016/j.ajog.2020.02.005. Epub 2020 Feb 15. Am J Obstet Gynecol. 2020. PMID: 32067967
-
Extending the safety evidence for opportunistic salpingectomy in prevention of ovarian cancer: a cohort study from British Columbia, Canada.Am J Obstet Gynecol. 2018 Aug;219(2):172.e1-172.e8. doi: 10.1016/j.ajog.2018.05.019. Epub 2018 May 28. Am J Obstet Gynecol. 2018. PMID: 29852159
-
ACOG Committee Opinion No. 774 Summary: Opportunistic Salpingectomy as a Strategy for Epithelial Ovarian Cancer Prevention.Obstet Gynecol. 2019 Apr;133(4):842-843. doi: 10.1097/AOG.0000000000003165. Obstet Gynecol. 2019. PMID: 30913193 Review.
-
Prophylactic salpingectomy for the prevention of ovarian cancer: Who should we target?Int J Cancer. 2020 Sep 1;147(5):1245-1251. doi: 10.1002/ijc.32916. Epub 2020 Feb 29. Int J Cancer. 2020. PMID: 32037528 Review.
Cited by
-
Unveiling the Promise: A Comprehensive Review of Salpingectomy as a Vanguard for Ovarian Cancer Prevention.Cureus. 2024 Jan 28;16(1):e53088. doi: 10.7759/cureus.53088. eCollection 2024 Jan. Cureus. 2024. PMID: 38414692 Free PMC article. Review.
-
Bilateral Oophorectomy Prevalence Among U.S. Women.J Womens Health (Larchmt). 2024 Nov;33(11):1457-1463. doi: 10.1089/jwh.2023.1134. Epub 2024 Jul 16. J Womens Health (Larchmt). 2024. PMID: 39011627 Free PMC article.
-
Ovarian Cancer: From Precursor Lesion Identification to Population-Based Prevention Programs.Curr Oncol. 2023 Nov 29;30(12):10179-10194. doi: 10.3390/curroncol30120741. Curr Oncol. 2023. PMID: 38132375 Free PMC article. Review.
-
Evaluating Ovarian Cancer Risk-Reducing Salpingectomy Acceptance: A Survey.Cancer Res Commun. 2025 Jan 1;5(1):187-194. doi: 10.1158/2767-9764.CRC-24-0566. Cancer Res Commun. 2025. PMID: 39785678 Free PMC article.
-
Ovarian cancer risk reduction by salpingectomy during non-gynaecological surgery: scoping review.BJS Open. 2024 Dec 30;9(1):zrae161. doi: 10.1093/bjsopen/zrae161. BJS Open. 2024. PMID: 39871731 Free PMC article.
References
-
- Canadian Cancer Society; Canadian cancer statistics 2022. November 2022. Accessed March 2023. https://cancer.ca/en/research/cancer-statistics/canadian-cancer-statistics.
-
- Beral V, Doll R, Hermon C, Peto R, Reeves G; Collaborative Group on Epidemiological Studies of Ovarian Cancer . Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371(9609):303-314. doi:10.1016/S0140-6736(08)60167-1 - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous